title: The Effect of tPA on Inpatient Rehabilitation after Stroke: A Cost Comparison.
abstract: BACKGROUND
  Tissue plasminogen activator has been found to significantly improve patient outcomes post stroke. Previous economic evaluations have adjusted for fewer admissions to inpatient rehabilitation but not for decreased length of stay in rehabilitation. Our objective was to estimate the potential cost savings associated with a decreased length of stay in inpatient rehabilitation for patients who receive tissue plasminogen activator compared to those who do not, in a Canadian context.
  
  
  METHODS
  Decreased length of stay in inpatient rehabilitation for patients who received tissue plasminogen activator compared to controls was reported previously in a population of 1962 patients admitted to hospital with an ischemic stroke in Ontario between July 1, 2003 and March 31, 2008. Average per diem cost savings associated with the use of tissue plasminogen activator were calculated using a literature based cost estimate. Sensitivity analysis varying the length of stay in inpatient rehabilitation was performed.
  
  
  RESULTS
  The estimated mean per diem cost of inpatient rehabilitation derived from the literature was $626. Based on previously reported estimates for reduced length of stay, receipt of tissue plasminogen activator was estimated to result in savings of $939 per patient during inpatient rehabilitation. Sensitivity analysis suggested that these cost savings could range from $501 to $1377 per patient on average.
  
  
  CONCLUSIONS
  Future economic evaluations of tissue plasminogen activator should consider adjusting for shortened length of stay in inpatient rehabilitation for patients who receive tissue plasminogen activator.
authors.forename: Marina
authors.initials: M
authors.lastname: Richardson
authors.forename: Matthew
authors.initials: M
authors.lastname: Meyer
authors.forename: Robert
authors.initials: R
authors.lastname: Teasell
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003365:Costs and Cost Analysis / Q000191:economics* / Q000379:methods; D005260:Female; D006760:Hospitalization / Q000191:economics* / Q000639:trends; D006801:Humans; D007902:Length of Stay / Q000191:economics / Q000639:trends; D008297:Male; D008875:Middle Aged; D009864:Ontario / Q000453:epidemiology; D020521:Stroke / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000191:economics*
chemical_list: D010959:Tissue Plasminogen Activator